Back to top
more

Madrigal Pharmaceuticals (MDGL)

(Delayed Data from NSDQ)

$210.98 USD

210.98
262,024

-0.34 (-0.16%)

Updated May 14, 2024 04:00 PM ET

After-Market: $210.53 -0.45 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MDGL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Madrigal Pharmaceuticals, Inc. [MDGL]

Reports for Purchase

Showing records 61 - 80 ( 184 total )

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 61

01/03/2020

Industry Report

Pages: 17

NASH Weekly: GLP-1 Data in 2Q20 Is Likely to Be Underwhelming

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 50.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 62

12/18/2019

Daily Note

Pages: 3

Madrigal Initiates Second Phase 3 Study, MAESTRO-NAFLD-1; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 63

12/12/2019

Daily Note

Pages: 3

Selloff an Overreaction, in Our View; Meanwhile MAESTRO-NAFLD-1 Opens for Enrollment

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 64

11/08/2019

Daily Note

Pages: 2

Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 65

11/07/2019

Company Report

Pages: 8

3Q Recap Awaiting Start of Second Phase 3, MAESTRO-NAFLD; Adjust PT to $215

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 66

11/06/2019

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 67

11/06/2019

Company Report

Pages: 8

3Q19 - Jack Of All Threats - Must Read

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 68

10/22/2019

Industry Report

Pages: 13

Healthcare - Should You Attend AASLD in Boston? Use Our Day-By-Day Calendar to Figure It Out

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 50.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 69

10/15/2019

Industry Report

Pages: 49

Final Program for Our Third Annual NASH Investor Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 70

10/07/2019

Industry Report

Pages: 48

Program for Our Third Annual NASH Investor Conference, October 21, New York

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 71

10/02/2019

Industry Report

Pages: 9

Healthcare - The Liver Meeting Abstracts Part 2: Our Coverage Universe

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 72

08/15/2019

Industry Report

Pages: 4

Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 73

08/08/2019

Company Report

Pages: 8

2Q19 Recap: Phase 3 MAESTRO-NASH Progressing Nicely; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 74

08/07/2019

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 75

08/07/2019

Company Report

Pages: 6

2Q19 - You Don''t Need An Army to Secure the Rapid MAESTRO Enrollment

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 76

07/08/2019

Industry Report

Pages: 3

Join Our Three-Part NASH Doc Series on "How Large is the NASH Opportunity?"

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 77

07/03/2019

Daily Note

Pages: 5

Madrigal Adds Commercial Expertise With New Appointment to Board; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 78

05/22/2019

Industry Report

Pages: 3

Healthcare -Recap of 34 Notes From Our Coverage of EASL 2019 and AASLD

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 79

05/09/2019

Company Report

Pages: 8

1Q19 Recap: MAESTRO-NASH Takes Center Stage; Phase 3 Dyslipidemia Study on Deck; Adjust PT to $225

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Madrigal Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 80

04/05/2019

Industry Report

Pages: 11

Healthcare - Walk Through Yas'' Shoes at EASL - Our EASL Roadmap

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party